Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.59 |
| ▸ | RIOK2 | Q9BVS4 | 2/20 | 0.50 |
| ▸ | GCK | P35557 | 2/20 | 0.50 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.50 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.49 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.49 |
| ▸ | SGMS2 | Q8NHU3 | 1/20 | 0.48 |
| ▸ | MAOB | P27338 | 2/20 | 0.48 |
| ▸ | GSK3A | P49840 | 1/20 | 0.47 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | CTSV | O60911 | 1/20 | 0.47 |
| ▸ | CTSL | P07711 | 1/20 | 0.47 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.47 |
| ▸ | LTA4H | P09960 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23795585 | 0.89 | MEN1 (0.57) | MEN1KMT2ARIOK2GCKNR4A2 | |
| SCHEMBL25675487 | 0.87 | NPC1 (0.60) | MEN1KMT2ARIOK2GCKNR4A2 | |
| SCHEMBL14156878 | 0.87 | RIOK2 (0.66) | MEN1KMT2ARIOK2GSK3AMAPK10 | |
| SCHEMBL25595329 | 0.86 | KMT2A (0.58) | MEN1KMT2ARIOK2GCKMAOB | |
| SCHEMBL25595258 | 0.86 | RIOK2 (0.52) | MEN1KMT2ARIOK2GCKNR4A2 | |
| SCHEMBL24008033 | 0.86 | MEN1 (0.52) | MEN1KMT2ARIOK2GCKNR4A2 | |
| SCHEMBL25604061 | 0.86 | MEN1 (0.52) | MEN1KMT2ARIOK2GCKNR4A2 | |
| SCHEMBL24007596 | 0.85 | ACVRL1 (0.59) | MEN1KMT2AGSK3AMAPK10 | |
| SCHEMBL14156884 | 0.85 | RAB9A (0.57) | MEN1KMT2ARIOK2NR3C2NPC1 | |
| SCHEMBL24008199 | 0.84 | MEN1 (0.50) | MEN1KMT2ARIOK2GCKNR4A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12037346-B2 | Amino-substituted heteroaryls for treating cancers with EGFR mutations | NUVALENT, INC. (US) | 2024-07-16 | — | — | US | disclosed |
| EP-4323356-A1 | AMINO-SUBSTITUTED HETEROCYCLES FOR TREATING CANCERS WITH EGFR MUTATIONS | Nuvalent, Inc. (US) | 2024-02-21 | — | — | EP | disclosed |
| WO-2022221227-A9 | AMINO-SUBSTITUTED HETEROCYCLES FOR TREATING CANCERS WITH EGFR MUTATIONS | NUVALENT, INC. (US) | 2023-11-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12037346-B2 | Amino-substituted heteroaryls for treating cancers with EGFR mutations | EGFR, ERBB2, ERBB3 | MEN1 3097/4885KMT2A 1625/4885RIOK2 2086/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.